Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multiple Dose, Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

NCT02098239 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02098239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02098239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multiple Dose, Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 1999
Completion date
May 31, 2002
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

jaundice, pancreatic cancer